A detailed history of Creative Planning transactions in Phathom Pharmaceuticals, Inc. stock. As of the latest transaction made, Creative Planning holds 33,884 shares of PHAT stock, worth $254,130. This represents 0.0% of its overall portfolio holdings.

Number of Shares
33,884
Previous 26,951 25.72%
Holding current value
$254,130
Previous $277,000 120.94%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 11, 2024

BUY
$10.25 - $19.5 $71,063 - $135,193
6,933 Added 25.72%
33,884 $612,000
Q2 2024

Aug 15, 2024

SELL
$8.97 - $12.05 $46,204 - $62,069
-5,151 Reduced 16.05%
26,951 $277,000
Q1 2024

May 10, 2024

BUY
$6.21 - $11.05 $66,757 - $118,787
10,750 Added 50.35%
32,102 $340,000
Q4 2023

Feb 14, 2024

BUY
$6.99 - $10.71 $6,130 - $9,392
877 Added 4.28%
21,352 $194,000
Q2 2023

Jul 21, 2023

BUY
$7.28 - $14.32 $3,458 - $6,802
475 Added 2.38%
20,475 $293,000
Q1 2023

May 15, 2023

BUY
$6.19 - $12.36 $123,800 - $247,200
20,000 New
20,000 $142,000

Others Institutions Holding PHAT

About Phathom Pharmaceuticals, Inc.


  • Ticker PHAT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,175,200
  • Market Cap $294M
  • Description
  • Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...
More about PHAT
Track This Portfolio

Track Creative Planning Portfolio

Follow Creative Planning and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Creative Planning, based on Form 13F filings with the SEC.

News

Stay updated on Creative Planning with notifications on news.